



IMPORTANT DRUG WARNING

SUBJECT: Risk of thrombotic and thromboembolic events following infusion of FEIBA VH or FEIBA NF, particularly following the administration of high doses and/or in patients with thrombotic risk factors.

Concerned Baxter Product: FEIBA VH [Anti-Inhibitor Coagulant Complex] and FEIBA NF [Anti-Inhibitor Coagulant Complex]

Dear Healthcare Professional:

Baxter Healthcare Corporation, in cooperation with the U.S. Food and Drug Administration (FDA), would like to inform you of an important safety update to the CONTRAINDICATIONS, WARNINGS and PRECAUTIONS sections of FEIBA [Anti-Inhibitor Coagulant Complex] prescribing information. FEIBA has been distributed in the United States under the trade name FEIBA VH (Vapor Heated) and FEIBA NF (Nanofiltered and Vapor Heated).

FEIBA [Anti-Inhibitor Coagulant Complex] is indicated for the control of spontaneous bleeding episodes or to cover surgical interventions in hemophilia A and hemophilia B patients with inhibitors.

Thrombotic and Thromboembolic Events Following Infusion of FEIBA VH or FEIBA NF

Risks associated with thrombotic and thromboembolic events have been previously described in the WARNINGS and PRECAUTIONS sections of the FEIBA prescribing information. Baxter and the FDA have continued to receive postmarketing reports of thromboembolic events, particularly following the administration of high doses and/or in patients with thrombotic risk factors. The type and number of these thrombotic and thromboembolic event reports received per time interval have remained consistent since initial U.S. licensure of FEIBA in 1986.

The existing WARNING relating to the risk of thrombotic and thromboembolic events has been updated in the prescribing information for FEIBA NF (the new trade name) with a Boxed Warning.

Specifically, the Boxed Warning includes the following important safety update:

BOXED WARNING:

Thrombotic and thromboembolic events have been reported during post-marketing surveillance following infusion of FEIBA VH or FEIBA NF, particularly following the administration of high doses and/or in patients with thrombotic risk factors (see Warnings, Precautions, and Adverse Reactions).

In addition, the **CONTRAINDICATIONS**, **WARNINGS**, and **PRECAUTIONS** sections in the package insert have been updated as follows:

The **CONTRAINDICATIONS** section has been updated to include:

- treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to coagulation factor VIII or coagulation factor IX
- patients with significant signs of disseminated intravascular coagulation (DIC)

The **WARNINGS** section has been updated to include examples of thrombotic and thromboembolic events, such as disseminated intravascular coagulation (DIC), venous thrombosis, pulmonary embolism, myocardial infarction, and stroke, that have been reported following infusion of FEIBA VH or FEIBA NF.

Additionally, the **WARNINGS** section has been updated to indicate that patients with disseminated intravascular coagulation (DIC), advanced atherosclerotic disease, crush injury, septicemia, or concomitant treatment with recombinant factor VIIa have an increased risk of developing thrombotic events due to circulating tissue factor (TF) or predisposing coagulopathy.

The following statements have been moved to the **WARNINGS** section:

Thromboembolic events are well recognized potential complications of FEIBA infusion.

FEIBA VH or FEIBA NF should not be given to patients with significant signs of disseminated intravascular coagulation (DIC) or fibrinolysis. Infusion of FEIBA should not exceed single dosage of 100 units per kg of body weight and daily doses of 200 units per kg body weight.

The **PRECAUTIONS** section has been updated to indicate that no adequate and well-controlled studies of the combined or sequential use of FEIBA VH or FEIBA NF and rFVIIa or antifibrinolytics have been conducted.

Additionally, the following statement was added to **PRECAUTIONS**:

Caution should be used when administering FEIBA VH or FEIBA NF to patients with an increased risk of thromboembolic complications. These include, but are not limited to, patients with a history of coronary heart disease, liver disease, disseminated intravascular coagulation, post-operative immobilization, elderly patients and neonates. In each of these situations, the potential benefit of treatment with FEIBA VH or FEIBA NF should be weighed against the risk of these complications. Patients who receive FEIBA VH or FEIBA NF should be monitored for development of signs or symptoms of DIC, acute coronary ischemia, and signs and symptoms of other thrombotic and thromboembolic events.



The updated prescribing information for FEIBA NF is enclosed.

Healthcare professionals should report adverse patient experiences to Baxter at 1-866-888-2472.

Should you have any questions regarding the use of FEIBA therapy, please contact Baxter Medical Information at 1-866-424-6724, or via email at medinfo@baxter.com, or by fax at 1-800-278-8704.

Reporting Adverse Events to FDA

You are encouraged to report suspected adverse events, regardless of causality to FDA's MedWatch reporting system:

- By phone (1-800-FDA-1088), by facsimile (1-800-FDA-0178)
- Online www.fda.gov/medwatch
- Mailed, using MedWatch FDA 3500 postage paid form, to the FDA Safety Information and Adverse Event Reporting Program, 5600 Fishers Lane, Rockville, MD 20852-9787.

Sincerely,



Bruce Ewenstein, MD, PhD
Vice President, Global Clinical and Medical Affairs

Baxter and FEIBA are registered trademarks of Baxter International Inc.

